» Articles » PMID: 36523322

Prognostic Biomarkers of Pancreatic Cancer Identified Based on a Competing Endogenous RNA Regulatory Network

Overview
Specialty Oncology
Date 2022 Dec 16
PMID 36523322
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pancreatic cancer is an insidious and heterogeneous malignancy with poor prognosis that is often locally unresectable. Therefore, determining the underlying mechanisms and effective prognostic indicators of pancreatic cancer may help optimize clinical management. This study was conducted to develop a prognostic model for pancreatic cancer based on a competing endogenous RNA (ceRNA) network.

Methods: We obtained transcriptomic data and corresponding clinicopathological information of pancreatic cancer samples from The Cancer Genome Atlas (TCGA) database (training set). Based on the ceRNA interaction network, we screened candidate genes to build prediction models. Univariate Cox regression analysis was performed to screen for genes associated with prognosis, and least absolute shrinkage and selection operator (LASSO) regression analysis was conducted to construct a predictive model. A receiver operating characteristic (ROC) curve was drawn, and the C-index was calculated to evaluate the accuracy of the prediction model. Furthermore, we downloaded transcriptomic data and related clinical information of pancreatic cancer samples from the Gene Expression Omnibus database (validation set) to evaluate the robustness of our prediction model.

Results: Eight genes (, , , , , , , and ) were used to construct the prediction model, which was confirmed as an independent predictor for evaluating the prognosis of patients with pancreatic cancer through univariate and multivariate Cox regression analysis. By plotting the decision curve, we found that the risk score model is an independent predictor has the greatest impact on survival compared to pathological stage and targeted molecular therapy.

Conclusions: An eight-gene prediction model was constructed for effectively and independently predicting the prognosis of patients with pancreatic cancer. These eight genes identified show potential as diagnostic and therapeutic targets.

Citing Articles

Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer.

Marin A, Sanchuki H, Namur G, Uno M, Zanette D, Aoki M Biomedicines. 2023; 11(4).

PMID: 37189687 PMC: 10136269. DOI: 10.3390/biomedicines11041069.

References
1.
Abou Khouzam R, Rao S, Venkatesh G, Zeinelabdin N, Buart S, Meylan M . An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated With an Immunosuppressed Tumor Microenvironment. Front Immunol. 2021; 12:680435. PMC: 8173254. DOI: 10.3389/fimmu.2021.680435. View

2.
Collisson E, Bailey P, Chang D, Biankin A . Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019; 16(4):207-220. DOI: 10.1038/s41575-019-0109-y. View

3.
Tay Y, Rinn J, Pandolfi P . The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505(7483):344-52. PMC: 4113481. DOI: 10.1038/nature12986. View

4.
Bailey P, Chang D, Nones K, Johns A, Patch A, Gingras M . Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016; 531(7592):47-52. DOI: 10.1038/nature16965. View

5.
Zhang T, Wang Y, Dong Y, Liu L, Han Y, Wang H . Identification of Novel Diagnostic Biomarkers in Prostate Adenocarcinoma Based on the Stromal-Immune Score and Analysis of the WGCNA and ceRNA Network. Dis Markers. 2022; 2022:1909196. PMC: 8783709. DOI: 10.1155/2022/1909196. View